Genetic identification of the main opportunistic mucorales by PCR-restriction fragment length polymorphism

被引:67
作者
Machouart, M [1 ]
Larché, J
Burton, K
Collomb, J
Maurer, P
Cintrat, A
Biava, MF
Greciano, S
Kuijpers, AFA
Contet-Audonneau, N
de Hoog, GS
Gérard, A
Fortier, B
机构
[1] CHU Brabois, Serv Parasitol Mycol, F-54511 Vandoeuvre Les Nancy, France
[2] CHU Brabois, Serv Reanimat Med, F-54511 Vandoeuvre Les Nancy, France
[3] Cent Bur Schimmelcultures, NL-3508 AD Utrecht, Netherlands
关键词
D O I
10.1128/JCM.44.3.805-810.2006
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Mucormycosis is a rare and opportunistic infection caused by fungi belonging to the order Mucorales. Recent reports have demonstrated an increasing incidence of mucormycosis, which is frequently lethal, especially in patients suffering from severe underlying conditions such as immunodeficiency. In addition, even though conventional mycology and histopathology assays allow for the identification of Mucorales, they often fail in offering a species-specific diagnosis. Due to the lack of other laboratory tests, a precise identification of these molds is thus notoriously difficult. In this study we aimed to develop a molecular biology tool to identify the main Mucorales involved in human pathology. A PCR strategy selectively amplifies genomic DNA from molds belonging to the genera Absidia, Mucor, Rhizopus, and Rhizomucor, excluding human DNA and DNA from other filamentous fungi and yeasts. A subsequent digestion step identified the Mucorales at genus and species level. This technique was validated using both fungal cultures and retrospective analyses of clinical samples. By enabling a rapid and precise identification of Mucorales strains in infected patients, this PCR-restriction fragment length polymorphism-based method should help clinicians to decide on the appropriate treatment, consequently decreasing the mortality of mucormycosis.
引用
收藏
页码:805 / 810
页数:6
相关论文
共 29 条
[1]   Apophysomyces elegans:: an emerging zygomycete in India [J].
Chakrabarti, A ;
Ghosh, A ;
Prasad, GS ;
David, JK ;
Gupta, S ;
Das, A ;
Sakhuja, V ;
Panda, NK ;
Singh, SK ;
Das, S ;
Chakrabarti, T .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (02) :783-788
[2]   Activity of posaconazole in treatment of experimental disseminated zygomycosis [J].
Dannaoui, E ;
Meis, JFGM ;
Loebenberg, D ;
Verweij, PE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (11) :3647-3650
[3]   In vitro susceptibilities of zygomycetes to conventional and new antifungals [J].
Dannaoui, E ;
Meletiadis, J ;
Mouton, JW ;
Meis, JFGM ;
Verweij, PE .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (01) :45-52
[4]  
De Hoog GS, 2000, ATLAS CLIN FUNGI, p[62, 101]
[5]  
Eucker J, 2001, MYCOSES, V44, P253, DOI 10.1111/j.1439-0507.2001.00656.x
[6]   Zygomycosis (mucormycosis): emerging clinical importance and new treatments [J].
Greenberg, RN ;
Scott, LJ ;
Vaughn, HH ;
Ribes, JA .
CURRENT OPINION IN INFECTIOUS DISEASES, 2004, 17 (06) :517-525
[7]   Diagnosis of infectious endocarditis in patients undergoing valve surgery [J].
Greub, G ;
Lepidi, H ;
Rovery, C ;
Casalta, JP ;
Habib, G ;
Collard, F ;
Fournier, PE ;
Raoult, D .
AMERICAN JOURNAL OF MEDICINE, 2005, 118 (03) :230-238
[8]   Experience with the MicroSeq D2 large-subunit ribosomal DNA sequencing kit for identification of filamentous fungi encountered in the clinical laboratory [J].
Hall, L ;
Wohlfiel, S ;
Roberts, GD .
JOURNAL OF CLINICAL MICROBIOLOGY, 2004, 42 (02) :622-626
[9]  
Holland Juliette, 1997, Current Topics in Medical Mycology, V8, P27
[10]   Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole [J].
Imhof, A ;
Balajee, SA ;
Fredricks, DN ;
Englund, JA ;
Marr, KA .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (05) :743-746